Tectonic Therapeutic (TECX) Net Income towards Common Stockholders (2017 - 2026)

Tectonic Therapeutic (TECX) has 10 years of Net Income towards Common Stockholders data on file, last reported at -$25.2 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 58.69% year-over-year to -$25.2 million in Q1 2026; TTM through Mar 2026 was -$83.5 million, a 42.3% decrease from a year earlier, with the FY2025 full-year figure at -$74.2 million, down 27.89% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$25.2 million, down from -$19.2 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for TECX reached as high as $67.5 million in Q2 2023 and fell as low as -$31.1 million in Q1 2022.
• Historically, Net Income towards Common Stockholders has averaged -$14.2 million across 5 years, with a median of -$19.0 million in 2025.
• Across the five-year window, Net Income towards Common Stockholders soared 340.52% in 2023 and sank 118.78% in 2024, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$25.0 million in 2022, then jumped by 68.57% to -$7.9 million in 2023, then slumped by 57.24% to -$12.4 million in 2024, then tumbled by 55.39% to -$19.2 million in 2025, then slumped by 31.29% to -$25.2 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$25.2 million in Q1 2026, -$19.2 million in Q4 2025, and -$19.0 million in Q3 2025.